Ichthyosiform Erythroderma, Corneal Involvement, and Hearing Loss (KID Syndrome): A Comprehensive Disease Report

MONDO ID: MONDO:0009440 · OMIM: #148210 · Orphanet: ORPHA:477 · Category: Mendelian (autosomal dominant ectodermal dysplasia)

Summary

Ichthyosiform Erythroderma, Corneal Involvement, and Hearing Loss is the formal disease-ontology name for Keratitis–Ichthyosis–Deafness (KID) syndrome, a rare congenital ectodermal dysplasia defined by a clinical triad: (1) vascularizing keratitis with progressive corneal opacification, (2) ichthyosiform erythroderma with palmoplantar keratoderma, and (3) profound, prelingual sensorineural hearing loss. The disorder is caused by autosomal dominant, predominantly de novo, gain-of-function missense mutations in GJB2, the gene encoding the gap-junction protein connexin 26 (Cx26) on chromosome 13q12.11. The single most frequent variant is p.Asp50Asn (p.D50N), accounting for the large majority of genotyped cases.

The unifying pathomechanism is the formation of aberrant, "leaky" connexin 26 hemichannels that are abnormally open at physiological extracellular calcium concentrations. This gain-of-function—rather than the simple loss of gap-junction communication that causes nonsyndromic deafness—drives the multisystem phenotype. In the epidermis, hyperactive hemichannels disrupt the calcium gradient and stratum-corneum lipid/permeability barrier, producing hyperkeratosis and erythroderma; in the cochlea, Cx26 dysfunction interrupts potassium recycling and cochlear development, producing deafness; and at the ocular surface, loss of Cx26 function in the corneal/limbal epithelium produces recurrent epithelial defects, neovascularization, and limbal stem-cell insufficiency. The degree of hemichannel gain-of-function correlates with clinical severity: the most electrophysiologically severe alleles (p.G45E, p.A88V) form constitutively open hemichannels and cause a uniformly lethal infantile multisystem form, whereas p.D50N is compatible with chronic lifelong survival.

Clinically, KID syndrome carries a substantial burden of chronic bacterial and fungal (notably Candida) infection and a 12–15% lifetime incidence of squamous cell carcinoma of skin and mucosa. Management is multidisciplinary and largely symptomatic—systemic retinoids (acitretin), aggressive infection surveillance, cochlear implantation, and complex ocular-surface surgery. Critically, the mechanistic understanding has enabled mechanism-based therapies: connexin hemichannel blockers (fenamates such as flufenamic and mefenamic acid) and hemichannel-antagonist antibodies delivered via AAV gene transfer both ameliorate epidermal pathology in transgenic mouse models and, in early human case reports, in patients.

Section 1 — Disease Information

Overview. KID syndrome is a rare autosomal dominant ectodermal disease characterized by the triad of keratitis (progressive, vascularizing corneal disease), ichthyosis (ichthyosiform erythroderma with palmoplantar keratoderma), and prelingual sensorineural deafness. It is caused by mutations in GJB2, which encodes connexin 26 located on chromosome 13q12.11 (PMID: 40635359: "a rare autosomal dominant ectodermal disease caused by mutations in the GJB2 gene, which encodes the gap junction protein Connexin 26 (Cx26) located on Chr. 13q12.11").

Key identifiers.

Synonyms / alternative names. Keratitis–ichthyosis–deafness syndrome; KID syndrome; HID syndrome (hystrix-like ichthyosis with deafness — molecularly identical to KID); ichthyosiform erythroderma, corneal involvement, and hearing loss; Senter syndrome; Desmons syndrome.

Data source. Information is derived from aggregated disease-level resources (OMIM, Orphanet) and from primary clinical literature comprising case reports and small case series (<100 total reported cases), plus in vitro electrophysiology and transgenic mouse studies. No large EHR-derived cohorts exist given the rarity of the disease.

Section 2 — Etiology

Primary cause (genetic). KID syndrome is a Mendelian disorder caused by heterozygous gain-of-function missense mutations in GJB2/Cx26. Inheritance is autosomal dominant, but the majority of cases are sporadic/de novo. In a cohort of 14 patients from 11 families, disease was sporadic in 7/11 families (64%) and familial in 4/11 (36%) (PMID: 17381453).

Genetic risk factors. The causal variants themselves are the risk determinants: - p.Asp50Asn (p.D50N; c.148G>A) — the predominant variant, present in ~86% of one genotyped cohort (PMID: 17381453: "Twelve patients (86%) were heterozygous for the p.Asp50Asn mutation and two patients (14%) were heterozygous for the p.Ser17Phe mutation"). - Additional recurrent alleles: p.Ser17Phe (S17F), p.Ala88Val (A88V), p.Asp50Ala (D50A), p.Gly45Glu (G45E, lethal), p.Gly12Arg (G12R, lethal), p.Asn54Lys (N54K). - Many pathogenic residues cluster in the first extracellular loop (E1) of Cx26, important for hemichannel docking and voltage gating (PMID: 15482471).

Environmental risk factors. No environmental cause of the disease itself; however, environmental triggers modulate complications. Peptidoglycan from the opportunistic pathogen Staphylococcus aureus (but not the commensal S. epidermidis) triggers hemichannel activity and IL-6 release specifically in KID-mutant keratinocytes, providing a genotype-linked mechanism for infection-driven inflammation (PMID: 22643125). UV exposure and chronic inflammation are presumed cofactors in the elevated SCC risk.

Protective factors. Elevated extracellular calcium suppresses the pathological hemichannel current in vitro and rescues cell death, and is the basis of therapeutic hemichannel blockade—but no established constitutional genetic or dietary protective factor is documented (PMID: 23447037).

Gene–environment interactions. The clearest documented GxE interaction is the differential response of KID-mutant Cx26 hemichannels to bacterial peptidoglycan: pathogen-derived (but not commensal-derived) PGN triggers ATP release and IL-6 induction selectively in KID-mutant cells, linking a specific genotype to an environmental (microbial) trigger of skin inflammation (PMID: 22643125).

Section 3 — Phenotypes

The core triad and associated phenotypes, with suggested HPO terms:

Frequency. The triad (keratitis, ichthyosis, deafness) is near-universal by definition, though corneal involvement (keratitis) can be absent in mild/atypical presentations. Sensorineural hearing loss is essentially 100% and is congenital/prelingual and severe-to-profound; in a cochlear-implant systematic review all patients had SNHL, predominantly severe to profound (PMID: 40889428; PMID: 40004458).

Ocular phenotype detail. Ocular signs include "loss of eyebrows and lashes, thickened and keratinized lids, trichiasis, recurrent corneal epithelial defects, superficial and deep corneal stromal vascularization with scarring, keratoconjunctivitis sicca, and … limbal insufficiency" (PMID: 15691545).

Atypical/expanded phenotype. Reported atypical features include neurological and skeletal anomalies (global developmental delay, seizures, ventriculomegaly, developmental hip dysplasia, torticollis), dental abnormalities (natal teeth), and follicular occlusion disorders (hidradenitis suppurativa, dissecting cellulitis) (PMID: 41305774; PMID: 39659087).

Quality-of-life impact. Substantial and multidomain: chronic visual impairment/blindness, deafness affecting communication and development, disfiguring skin disease, chronic pain and pruritus from infections, and cancer anxiety/surveillance burden. Formal EQ-5D/SF-36 data are not available for this ultra-rare disease.

Section 4 — Genetic / Molecular Information

Causal gene. GJB2 (gap junction protein beta 2; HGNC:4284), encoding connexin 26, chromosome 13q12.11. Disease OMIM #148210.

Pathogenic variant spectrum. All are heterozygous missense mutations classified pathogenic/likely pathogenic per ACMG/AMP:

Allele frequency. These are essentially absent from population databases (gnomAD) as they are dominant de novo disease-causing variants; they are not polymorphisms.

Origin. Germline; predominantly de novo. Germline (germinal) mosaicism is documented as a recurrence mechanism: healthy parents had two affected children heterozygous for p.D50N (PMID: 17381453: "a family in which we personally examined the healthy parents had two affected children heterozygous for the p.Asp50Asn mutation, suggesting germinal mosaicism").

Functional consequence. Gain of function — aberrant "leaky" hemichannel activity (not loss of function). Some KID mutations additionally exert a transdominant effect on wild-type connexin 43, creating leaky heteromeric hemichannels (PMID: 26775130).

Rare recessive form. A rare autosomal recessive KID phenotype has been reported with a novel homozygous pathogenic GJB2 variant (congenital erythroderma, SNHL, developmental delay) (PMID: 41453769), and GJB6 (Cx30) has been implicated less commonly.

Modifier genes / epigenetics / chromosomal abnormalities. No established modifier genes, epigenetic marks, or large-scale chromosomal abnormalities are associated; the phenotype is driven by the single point mutation, with genotype being the principal determinant of severity. Variable expressivity even within the same genotype (p.D50N) is well documented (PMID: 33136289).

Section 5 — Environmental Information

• Environmental factors: No causal toxin/radiation/pollution exposure. UV and chronic wound inflammation likely contribute to squamous cell carcinoma risk (not proven mechanistically in KID specifically).
• Lifestyle factors: Not established as causal. General skin-cancer risk factors (sun exposure) are relevant to surveillance.
• Infectious agents: Infections are complications and modulators, not causes. Chronic bacterial (including Klebsiella, Staphylococcus aureus) and fungal (Candida) infections are characteristic (PMID: 25546246; PMID: 20846357). S. aureus-derived peptidoglycan selectively triggers KID-mutant hemichannels (PMID: 22643125). Chronic candidiasis can produce verrucous plaques mimicking SCC (PMID: 29742560; PMID: 28111777).

Section 6 — Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

1. De novo heterozygous missense mutation in GJB2 (e.g., p.D50N, p.G45E, p.A88V)
   → alters connexin 26 residues in the N-terminus / TM domains / E1 extracellular loop.
│
▼
2. Mutant Cx26 oligomerizes into hexameric connexons that reach the cell surface but
   form ABERRANT "LEAKY" HEMICHANNELS
   → loss of normal inhibition by extracellular Ca²⁺, altered voltage gating,
     altered conductance/rectification (gain of function).
│
├──(branch, some alleles)──► transdominant modification of wild-type Cx43
│                              → additional leaky heteromeric hemichannels.
▼
3. Hemichannels are abnormally OPEN at physiological Ca²⁺
   → excess transmembrane current, ATP leak, ionic dysregulation.
│
├───────────────► SKIN branch
│   4a. Disrupted epidermal Ca²⁺ gradient + abnormal stratum-corneum lipid
│       composition → defective permeability/water barrier.
│   5a. Keratinocyte hyperproliferation, altered keratin expression, and
│       (in low Ca²⁺ / high hemichannel activity) accelerated cell death.
│   6a. → ichthyosiform erythroderma, palmoplantar keratoderma; barrier
│       failure → recurrent infection → (chronic inflammation, UV) → SCC.
│
├───────────────► COCHLEA branch
│   4b. Loss/dysfunction of Cx26 in cochlear gap-junction networks
│       (epithelial + connective-tissue) → interrupted K⁺ recycling AND
│       impaired neonatal organ-of-Corti development.
│   5b. → K⁺ "intoxication" of the organ of Corti / failed maturation.
│   6b. → profound prelingual sensorineural hearing loss.
│
└───────────────► OCULAR SURFACE branch
    4c. Cx26 dysfunction in corneal/limbal epithelium → epithelial fragility,
        limbal stem-cell insufficiency.
    5c. → recurrent corneal epithelial defects, neovascularization, scarring.
    6c. → vascularizing keratitis, corneal opacification, visual loss.

Severity modifier: the MORE constitutively open the hemichannel (G45E, A88V >> D50N),
the more severe → up to a uniformly lethal multisystem infantile form.

Where inferred: the direct causal role of leaky hemichannels in the epidermal and cochlear phenotypes is demonstrated in transgenic mouse models and electrophysiology; the precise contribution of Cx43 transdominance and the exact ocular-surface cellular mechanism are partly inferred from in vitro and expression data.

Core mechanism — leaky hemichannel gain-of-function

The unifying molecular defect is aberrant hemichannel activity. Cx26-D50A and Cx26-A88V "form active hemichannels that significantly increase membrane current flow compared with wild-type Cx26. This increased membrane current accelerated cell death in low extracellular calcium solutions" (PMID: 23447037). The lethal G45E allele "forms constitutively active connexin hemichannels" (PMID: 22031297). The most common D50N mutation "produces multiple aberrant hemichannel properties, including loss of inhibition by extracellular Ca²⁺, decreased unitary conductance, increased open hemichannel current rectification and voltage-shifted activation" (PMID: 23797419). Glycine-45 is a conserved Ca²⁺ sensor for hemichannel gating conserved across cochlear connexins (PMID: 23756814).

Genotype → severity correlation. The degree of cell death and gain-of-function predicts the severity of both skin disease and hearing loss (PMID: 28428247).

Downstream epidermal mechanism

Hyperactive hemichannels corrupt the epidermal calcium gradient and lipid barrier: transgenic mouse models expressing Cx26 KID mutations "reproduce human phenotypes and present impaired epidermal calcium homeostasis and abnormal lipid composition of the stratum corneum affecting the water barrier" (PMID: 26777423). Different mutations "can either form dominant hemichannels with altered calcium regulation or increased calcium permeability, leading to clinical subtypes" and can "transdominantly alter the function of wild-type connexin 43 and create leaky heteromeric hemichannels" (PMID: 26775130).

Cochlear mechanism

Two cochlear gap-junction networks recycle K⁺ from hair cells back to the endolymph; loss of Cx26 function "would disrupt the recycling of potassium … leading to a local intoxication of the Corti's organ by potassium, leading to the hearing loss" (PMID: 10928803; PMID: 11810458). Cx26 is additionally required for neonatal organ-of-Corti maturation before the onset of hearing, implying a developmental as well as a homeostatic component (PMID: 25251605).

Suggested ontology terms. GO: gap junction hemichannel activity (GO:0055077 / connexin-containing hemichannel), regulation of transmembrane transport, cellular calcium ion homeostasis (GO:0006874), potassium ion transmembrane transport (GO:0071805), keratinocyte differentiation (GO:0030216), epidermis development (GO:0008544). CL: keratinocyte (CL:0000312), cochlear outer/inner hair cell (CL:0000601/CL:0000589), cochlear supporting cell, corneal epithelial cell (CL:0000575), limbal stem cell. UBERON: epidermis (UBERON:0001003), stratum corneum (UBERON:0002027), cornea (UBERON:0000964), corneal epithelium (UBERON:0001772), organ of Corti (UBERON:0002227), stria vascularis (UBERON:0002393). CHEBI: calcium(2+) (CHEBI:29108), potassium(1+) (CHEBI:29103), ATP (CHEBI:15422).

Section 7 — Anatomical Structures Affected

• Primary organs: Skin/epidermis (whole integument), cornea and ocular surface, cochlea/inner ear.
• Secondary/complications: Mucous membranes (oral/tongue), hair follicles and adnexa (alopecia, follicular occlusion disorders), nails, teeth; rarely brain (ventriculomegaly) and skeleton in atypical cases.
• Body systems: Integumentary, special-sense (auditory and ocular), with variable neurological/musculoskeletal involvement.
• Tissues: Stratified squamous epithelium (epidermis, corneal/limbal epithelium), cochlear neuroepithelium and connective-tissue fibrocytes.
• Cell populations (CL): Keratinocytes, corneal/limbal epithelial cells and limbal stem cells, cochlear supporting cells, fibrocytes, and hair cells (indirectly).
• Subcellular (GO CC): Plasma membrane connexin hemichannel/gap junction (connexin complex GO:0005922; gap junction GO:0005921).
• Localization/lateralization: Bilateral and largely symmetric for deafness and ocular involvement; skin involvement is generalized.

Section 8 — Temporal Development

• Onset: Congenital. Skin disease frequently presents at birth (erythroderma, sometimes a collodion membrane or thick vernix-like covering). Hearing loss is congenital/prelingual. Keratitis typically emerges and progresses through childhood.
• Progression: Skin disease is chronic and lifelong with progressive hyperkeratosis; keratitis is progressive and can lead to blindness; hearing loss is stable (already profound). Cancer risk accrues over the lifespan.
• Disease course: Chronic, non-remitting for the classic form. For the lethal genotypes (G45E, A88V, G12R), the course is fulminant with infantile death.
• Critical periods: Neonatal period is critical both for cochlear intervention (Cx26 required for organ-of-Corti maturation before hearing onset — early cochlear implantation is favored) and for skin-barrier/infection management. Early death in lethal genotypes concentrates in infancy.

Section 9 — Inheritance and Population

• Epidemiology: Ultra-rare; fewer than ~100 cases reported in the literature. No reliable prevalence/incidence estimates (Orphanet lists it as <1/1,000,000). No sex predilection established.
• Inheritance: Autosomal dominant, predominantly de novo. Sporadic in ~64% and familial in ~36% of families in one series (PMID: 17381453). A rare autosomal recessive form exists (PMID: 41453769).
• Penetrance: High/complete for carriers of pathogenic dominant alleles.
• Expressivity: Variable, even among patients sharing the identical p.D50N mutation (PMID: 33136289; PMID: 26810281).
• Germline mosaicism: Documented (recurrence in siblings of unaffected parents) (PMID: 17381453).
• Founder effects / carrier frequency / consanguinity: Not applicable to the dominant de novo form (no carrier state); consanguinity relevant only to the rare recessive form.
• Geographic/ethnic distribution: No specific population enrichment; reported worldwide.

Section 10 — Diagnostics

• Clinical diagnosis: Based on the characteristic triad plus supportive skin histology. Histology shows acanthosis and papillomatosis of the epidermis with basket-weave hyperkeratosis (PMID: 20846357).
• Genetic testing (confirmatory): GJB2 single-gene sequencing is the primary confirmatory test; gene panels for congenital ichthyosis/syndromic hearing loss and whole-exome sequencing are useful when the diagnosis is uncertain (PMID: 42194992). Detection of p.D50N (c.148G>A) or another recurrent pathogenic GJB2 variant confirms diagnosis.
• Audiology: Auditory brainstem response / audiometry confirm severe-to-profound bilateral SNHL.
• Ophthalmology: Slit-lamp exam documents keratitis, neovascularization, limbal insufficiency.
• Biopsy caution: Because SCC risk is high and chronic infection (candidiasis, verruciform xanthoma) can mimic SCC histologically, suspicious lesions require careful biopsy and clinicopathologic correlation (PMID: 28111777; PMID: 31710113).
• Differential diagnosis: Other dominant GJB2 skin-plus-deafness disorders — HID syndrome (identical mutation), Vohwinkel syndrome, Bart-Pumphrey syndrome, palmoplantar keratoderma with deafness — plus Clouston syndrome (GJB6/Cx30), which a mild p.D50N patient may resemble (PMID: 15482471; PMID: 12072059; PMID: 26810281).

Section 11 — Outcome / Prognosis

• Genotype-dependent survival: Prognosis is dominated by genotype. p.G45E and p.A88V are uniformly lethal in infancy: "Infant death occurred in all patients with GJB2 p.G45E and p.A88V; it is unusual with other GJB2 mutations" (PMID: 30287322). p.G12R also causes early death (PMID: 31099403). The common p.D50N is compatible with chronic lifelong survival.
• Morbidity/mortality drivers: In lethal cases, "during life all had ≥1 serious infection; most had poor weight gain and severe respiratory difficulties; many had additional anatomic abnormalities" (PMID: 30287322). Sepsis/meningitis (e.g., ESBL Klebsiella) can be fatal in neonates (PMID: 20846357).
• Cancer: 12–15% incremental incidence of squamous cell carcinoma of mucous membranes and skin — a major long-term threat, including fatal tongue carcinoma and ocular surface squamous neoplasia (PMID: 29023238; PMID: 30653245).
• Functional outcomes: Deafness and progressive vision loss are the dominant disabilities; chronic disfiguring skin disease and recurrent infection add substantial morbidity.
• Prognostic factors: Genotype (most important), degree of hemichannel gain-of-function, infection burden, and cancer surveillance.

Section 12 — Treatment

Management is multidisciplinary and largely symptomatic, with emerging mechanism-based options.

Pharmacotherapy

• Systemic retinoids (acitretin, NCIT: Acitretin): Improve hyperkeratosis; oral acitretin 0.5–1.0 mg/kg/day improves skin and can even reverse KID-related visual impairment (PMID: 29159249; PMID: 33136289; PMID: 20846357).
• Emollients/keratolytics for skin barrier support.
• Antimicrobials/antifungals (e.g., oral fluconazole) for chronic bacterial/fungal infection, which can dramatically resolve verrucous candidal plaques (PMID: 29742560).

Mechanism-based (emerging) therapies

• Connexin hemichannel blockers — fenamates: Topical flufenamic acid blocked Cx26-G45E hemichannel activity in vitro and "substantially reduced epidermal pathology in vivo, compared to untreated, or vehicle treated control animals" (PMID: 34916582); disease recurred on treatment cessation. Topical mefenamic acid produced remarkable improvement in a pediatric patient — "which responded remarkably well to topical mefenamic acid, offering a potential novel therapy" (PMID: 40814260).
• Hemichannel-antagonist antibody + gene transfer: AAV-delivered blocking monoclonal antibody "significantly reduced the size and thickness of KID lesions … blocking activity of mutant HCs in the epidermis in vivo" (PMID: 36736132); a related antibody alleviated symptoms in a Clouston (Cx30) mouse model (PMID: 32553574).

Auditory rehabilitation

• Cochlear implantation provides significant benefit — average hearing improvement 45 dB (range 28–60 dB) (PMID: 40889428); speech discrimination improved in ~89% (PMID: 40004458) — but with elevated post-operative wound infection/dehiscence (skin complications ~78.6% in one review), requiring careful surgical planning.

Ocular / surgical

• Ocular-surface management is complex and often unsatisfactory: lubrication, keratectomy, limbal allograft, amniotic membrane transplant, tarsorrhaphy, lamellar keratoplasty, systemic immunosuppression, and keratoprosthesis (Boston KPro) in advanced cases; useful vision is frequently not preserved (PMID: 15691545; PMID: 40721026; PMID: 42577860).
• Oncologic surgery for SCC; wound care can be challenging (dehiscence, requiring negative-pressure therapy) (PMID: 39749122).

Suggested NCIT terms: Acitretin, Retinoid Therapy, Fluconazole, Cochlear Implantation, Keratoplasty, Antibody Therapy, Gene Therapy.

Section 13 — Prevention

• Primary prevention: Not possible for de novo mutations. Genetic counseling is central for affected families given autosomal dominant inheritance and documented germline mosaicism (recurrence risk even with unaffected parents).
• Prenatal / reproductive options: Prenatal diagnosis and preimplantation genetic testing are available once the familial GJB2 variant is known.
• Secondary prevention: Regular dermatologic surveillance for squamous cell carcinoma (biopsy of suspicious/verrucous lesions), aggressive infection control, ophthalmologic monitoring, and early audiologic intervention.
• Tertiary prevention: Infection prophylaxis/prompt treatment, ocular-surface protection, meticulous cochlear-implant wound care to mitigate the high skin-complication rate.

Section 14 — Other Species / Natural Disease

• Taxonomy: Human disease (NCBI Taxon 9606). No naturally occurring animal counterpart of KID syndrome is established. (Note: "Floppy Kid Syndrome" in goats is an unrelated metabolic condition — a naming coincidence, not this disease.)
• Orthologous gene: Mouse Gjb2 (Cx26) is the ortholog used to build disease models.
• Comparative biology: Glycine-45 and adjacent E1-loop residues are conserved across cochlear connexins (Cx26, Cx30, Cx32, Cx43), and G45E produces analogous leaky-hemichannel, Ca²⁺-rescuable cell death when introduced into Cx30/32/43 — indicating deep evolutionary conservation of the Ca²⁺-gating mechanism (PMID: 23756814).

Section 15 — Model Organisms

• Mouse models (mammalian, in vivo): Transgenic mice expressing Cx26 KID mutations (notably Cx26-G45E) recapitulate human epidermal phenotypes and demonstrate impaired epidermal calcium homeostasis and abnormal stratum-corneum lipid composition (PMID: 26777423; PMID: 22031297). These models were the platform for demonstrating fenamate and antibody hemichannel-blockade efficacy (PMID: 34916582; PMID: 36736132). Conditional Gjb2-null mice reveal the developmental cochlear requirement for Cx26 (PMID: 25251605).
• In vitro / cellular models: Xenopus oocytes, HeLa (connexin-deficient), HEK293, HaCaT keratinocytes, and primary human keratinocytes expressing mutant Cx26 — used for electrophysiology, dye-uptake, ATP-release, and cell-death assays (PMID: 23447037; PMID: 22643125).
• Phenotype recapitulation / limitations: Mouse models reproduce skin disease well and enable therapeutic testing; recapitulation of the full human triad (especially the ocular and auditory phenotypes together) and long-term cancer risk is incomplete.
• Resources: MGI (Gjb2), IMPC/KOMP for conditional alleles.

Mechanistic Model / Interpretation

KID syndrome is best understood as a connexin-hemichannel gain-of-function channelopathy with tissue-specific consequences dictated by where Cx26 is essential (epidermis, cochlea, ocular surface). A single point mutation converts a normally tightly regulated hemichannel—closed at physiological extracellular Ca²⁺—into a leaky conduit. The clinical severity is a near-monotonic function of how "open" the mutant channel is:

This genotype–electrophysiology–phenotype ladder (PMID: 28428247; PMID: 30287322) is the report's central integrative insight: the same molecular lesion, scaled by biophysical severity, produces a spectrum from a survivable chronic disease to a fatal neonatal multisystem disorder. Crucially, because the pathology is driven by excess channel activity (not absence of protein), it is pharmacologically reversible in principle — the basis for the fenamate and antibody therapies that work without reducing mutant protein expression.

Evidence Base (key literature)

Evidence source types: human clinical (case reports/series, systematic reviews), model organism (transgenic/conditional mice), in vitro (oocyte/HeLa/keratinocyte electrophysiology), and computational (E1-loop pore modeling, PMID: 39302316).

Limitations and Knowledge Gaps

1. Ultra-rarity: <100 reported cases; no population-level prevalence/incidence, no QoL instrument data, no controlled therapeutic trials — evidence is dominated by case reports and mechanistic studies.
2. Ocular mechanism is less molecularly resolved than the skin and cochlear mechanisms; the precise limbal stem-cell/corneal epithelial cellular pathway is largely inferred.
3. Genotype–phenotype variability: even identical p.D50N patients show markedly different severity, implying unidentified modifiers (genetic/epigenetic/environmental) not yet characterized.
4. Therapeutics: fenamate and antibody/gene therapies are validated mainly in mice and isolated human cases; durability, safety, systemic delivery, and efficacy for the ocular and auditory phenotypes are unproven.
5. Cancer biology: the molecular link between leaky hemichannels and squamous carcinogenesis is not mechanistically established.

Proposed Follow-up Experiments / Actions

1. Prospective multicenter natural-history registry capturing genotype, survival, cancer incidence, and standardized QoL/audiologic/ophthalmologic outcomes.
2. Clinical trial of topical fenamates (flufenamic/mefenamic acid) for KID skin disease, with predefined endpoints and safety monitoring, building on positive mouse and case-report data.
3. Ocular-directed mechanistic study (patient-derived limbal organoids/iPSC corneal epithelium) to define the corneal hemichannel pathway and test hemichannel blockers on the ocular surface.
4. Modifier discovery: WES/WGS + multi-omics on discordant p.D50N patients to identify severity modifiers.
5. Systemic hemichannel-antagonist antibody / AAV gene-transfer development targeting all three affected epithelia, with dose-ranging in transgenic models.
6. Standardized SCC surveillance protocol and biopsy algorithm distinguishing carcinoma from candidal/verruciform mimics.
7. Optimized cochlear-implant surgical pathway to reduce the high wound-infection/dehiscence rate specific to KID skin.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0009440 (2 mentions) - the report calls it "MONDO"; MONDO calls it ichthyosiform erythroderma, corneal involvement, and hearing loss
• HP:0000982 (1 mention) - the report calls it "Moderate–severe, stable–progressive"; HP calls it Palmoplantar keratoderma
• HP:0000407 (1 mention) - the report calls it "Severe–profound, stable"; HP calls it Sensorineural hearing impairment
• HP:0001596 (1 mention) - the report calls it "Variable"; HP calls it Alopecia
• HP:0002860 (1 mention) - the report calls it "12–15% incidence, may be fatal"; HP calls it Squamous cell carcinoma
• HP:0008404 (1 mention) - the report calls it "Variable"; HP calls it Nail dystrophy
• HP:0000613 (1 mention) - the report calls it "Variable"; HP calls it Photophobia

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.